Core Points - The company and its subsidiaries obtained 36 domestic medical device registration/filing certificates, 6 intellectual property qualifications, and 6 overseas certifications between July and September 2025 [1] Group 1: Domestic Medical Device Registration - The company received 36 domestic medical device registration/filing certificates, enhancing its product offerings in the medical device sector [1] Group 2: Intellectual Property Qualifications - The company secured 6 intellectual property qualifications, which include patent certificates and computer software copyright registration certificates, contributing to a stronger intellectual property protection system [1] Group 3: Overseas Certifications - The company obtained 6 overseas certifications, including CE certificates, which will facilitate the expansion of its products into international markets [1] Group 4: Impact on the Company - The acquisition of these qualifications is expected to enrich the company's product variety, improve its intellectual property protection framework, expand its product layout in tumor screening and precision diagnosis, and enhance its core competitiveness in overseas applications [1]

Group 1 - The major shareholder, Zhuhai Gaotejia, and its associates held a total of 10,309,059 shares, accounting for 11.0178% of the company's total share capital before the reduction plan [1][2] - The reduction plan allowed for a maximum of 2,806,977 shares to be sold, representing up to 3.00% of the company's total share capital [2] - The actual reduction resulted in the sale of 2,144,897 shares, which is 2.2923% of the total share capital, completed within the disclosed timeframe [2][3] Group 2 - The equity change does not trigger a mandatory tender offer and will not alter the company's controlling shareholder or actual controller [3][5] - The reduction was consistent with the previously disclosed plan, and the minimum reduction quantity was achieved [4] - The completion of the reduction plan is expected to have no significant impact on the company's governance structure or future operations [5] Group 3 - In the first quarter of 2025, the company and its subsidiaries obtained 9 domestic medical device registration/filing certificates and 14 intellectual property qualifications [7] - The acquisition of these qualifications is expected to enhance the company's product variety and strengthen its intellectual property protection system, particularly in the fields of tumor screening and precision diagnosis [7]